オリタバンシンジフォスファート

プロパティ

安全情報

説明

Oritavancin diphosphate is a glycopeptide analog related to the vancomycin class of antibiotics that inhibits the transpeptidase and transglycosylation steps of bacterial peptidoglycan cell-wall synthesis. The compound was discovered and initially developed by Eli Lilly and Co. The development of the compound was sold to Intermune and then to Targanta which was acquired by The Medicines Company who achieved approval of the drug by the US FDA for the treatment of acute bacterial skin and skin-structure infections caused by gram-positive bacteria. It is also approved for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.